GlassScriptPhysician profile
Jamal Akhtar
NPI 1336692953
$3,001.16
in general payments reported to CMS, 2019-2025
26 companies · $1,176 in 2025
The $1,176 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2021: $14.24 · 2022: $381 · 2023: $592 · 2024: $687 · 2025: $1,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,255 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,255.08 |
| Education | $200.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $573.67 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Jazz Pharmaceuticals INC. | $443.69 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $304.03 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $234.32 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $205.57 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $189.87 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $157.40 | 2022-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $119.07 | 2019-2025 | |
| Harmony Biosciences LLC | $107.18 | 2023-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.95 | 2019-2025 | Jascayd, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.05 | 2024-2025 | Xifaxan |
| Inspire Medical Systems, INC. | $74.43 | 2024 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $51.89 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $42.28 | 2023-2025 | Lumryz |
| Mylan Specialty L.P. | $38.33 | 2023-2024 | Yupelri |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $35.02 | 2025 | Ibsrela |
| Grifols USA, LLC | $34.94 | 2025 | Prolastin-C Liquid |
| Dynavax Technologies Corporation | $34.72 | 2024 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $31.80 | 2022 | |
| Axsome Therapeutics, INC. | $27.13 | 2025 | Sunosi |
| Azurity Pharmaceuticals, INC. | $21.30 | 2025 | Horizant |
| Dexcom, INC. | $20.71 | 2025 | Dexcom G6 Transmitter |
| Shire North American Group INC | $18.18 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $15.68 | 2025 | Opsumit, Uptravi |
| Sunovion Pharmaceuticals INC. | $14.57 | 2019 | |
| Merck Sharp & Dohme LLC | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamal Akhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.